Advocacy intelligence hub — real-time data for patient organizations
NiKang Therapeutics, Inc. — PHASE1
University of Alabama at Birmingham — PHASE1, PHASE2
Australia New Zealand Gynaecological Oncology Group — PHASE2
NRG Oncology — PHASE3
Memorial Sloan Kettering Cancer Center — PHASE2
National Cancer Institute (NCI) — PHASE3
North Eastern German Society of Gynaecological Oncology — PHASE2
Immatics US, Inc. — PHASE1, PHASE2
National Cancer Institute (NCI) — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Ramez N Eskander, M.D
NRG Oncology
📍 ENCINITAS, CA
Cristina DeCesaris, MD, M.D
Huntsman Cancer Institute/ University of Utah
📍 WYNNEWOOD, PA
Floor Backes
NRG Oncology
Margaret von Mehren
Fox Chase Cancer Center
Britt K Erickson
NRG Oncology
Robert Maki, MD, PhD, MD, PhD
Memorial Sloan Kettering Cancer Center
📍 PHILADELPHIA, PA